Toggle Nav
Close
  • Menu
  • Setting

EZ Cap™ Mouse RLI mRNA (m1Ψ)

Catalog No.
R1075
Mouse RLI mRNA with Cap 1 structure, modified by N1-Methylpseudo-UTP (m1Ψ), providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.
Grouped product items
SizePriceStock Qty
100ug (1mg/mL)
$210.00
In stock
1mg (1mg/mL)
$1,136.00
In stock
5x1mg (1mg/mL)
$4,090.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

RLI, a fusion protein composed of interleukin-15 (IL-15) and the sushi domain of its receptor IL-15Rα, is an innovative immunotherapeutic agent. As an important cytokine, IL-15 has the ability to stimulate the proliferation of natural killer cells (NK cells) and T cells, thereby enhancing the anti-tumor and antiviral response of the immune system. However, the biological activity of IL-15 depends on binding to its receptor IL-15Rα. By fusing IL-15 with the sushi domain of IL-15Rα, the resulting fusion protein RLI stabilizes the activity of IL-15 and prolongs its half-life in vivo. This design not only improves the bioavailability of IL-15, but also reduces the toxicity that may be induced by IL-15 alone. IL-15/IL-15Rα-sushi fusion protein has shown potential in cancer immunotherapy to enhance the function of immune cells and promote the clearance of tumor cells. Studies have shown that this fusion protein has significant antitumor activity in a variety of cancer models, and has become an important research direction in the field of immunotherapy.

EZ Cap™ Mouse RLI mRNA (m1Ψ) is provided at a concentration of ~1 mg/ml with Cap1 structure. There are currently two ways to cap mRNA: One is co-transcription method, by adding Cap analogues into the transcription process. The other is enzymatic Capping. After transcription, Cap0 capping is performed by Vaccinia virus Capping Enzyme (VCE), GTP and S-adenosylmethionine (SAM). The Cap0 is then generated into the Cap1 through 2´-O-Methyltransferase and SAM. Cap1 Capping can also be performed by adding VCE, 2´-O-Methyltransferase, GTP and SAM in a one-step process. Cap 1 structure is more ideal for mammalian systems and possess higher transcription efficiency than Cap 0 structure. The addition of N1-Methylpseudo-UTP(m1Ψ) and poly(A) tail suppress RNA-mediated innate immune activation and increase the stability and lifetime of the mRNA in vitro and in vivo. Poly(A) tail also plays an important role in enhancing the efficiency of translation initiation.

Quality Control

Quality Control & MSDS

View current batch:
 

Description

mRNA Length

951 nucleotides

Concentration

~1 mg/mL

Buffer

1 mM Sodium Citrate, pH 6.4

Storage

-40°C or below

General tips

Please dissolve it on ice and protect from RNase carefully. Avoid repeated freeze/thaw cycles as possible. Don’t vortex. Upon first use, centrifuge the tube softly and aliquot it into several single use portions. Use RNase-free reagents and materials with appropriate RNase-free technique. Don’t add to the media with serum unless mixing with a transfection reagent.

Shipping Condition

ship with dry ice